News Immutep Limited

Equities

IMM

AU000000IMM6

Market Closed - Australian S.E. Other stock markets 11:40:31 06/05/2024 am IST			5-day change	1st Jan Change
0.47 ^AUD	+8.05%		+5.62%	+36.23%

02/05	Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	CI
02/05	Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	02/05	AQ
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	02/05	CI
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	02/05	MT
Canaccord Starts Immutep at Buy, Price Target is AU$1.00	30/04	MT
Immutep Quarterly Activities Report Q3 FY24	29/04	AQ
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression	25/04	CI
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	25/04	MT
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B	24/04	CI
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761	18/04	AQ
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761	18/04	CI
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	18/04	PU
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial	18/04	MT
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76	18/04	PU
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	17/04	AQ
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	17/04	CI
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay	17/04	MT
Immutep Obtains Support from Spanish Health Agency for Efti Registrational Trial	17/04	MT
Immutep : Corporate Presentation	26/03	PU
Encouraging results for Immutep's cancer therapies	25/03	FI
Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)	06/03	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Immutep Limited

Equities

IMM

AU000000IMM6

Summary

Filters